<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977860</url>
  </required_header>
  <id_info>
    <org_study_id>09-031</org_study_id>
    <nct_id>NCT00977860</nct_id>
  </id_info>
  <brief_title>Hypofractionated SBRT For Prostate Cancer</brief_title>
  <official_title>Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adam Olson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts,&#xD;
      the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity&#xD;
      observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free&#xD;
      Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at&#xD;
      2 years following hypofractionated stereotactic body radiation therapy for low and&#xD;
      intermediate risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiosurgery should be ideal for treating prostate cancer because:&#xD;
&#xD;
        -  targeting accuracy for static targets is excellent, with an error of about 1mm,&#xD;
&#xD;
        -  it can adjust for intra-fractional organ motion, reducing the volume of the target PTV&#xD;
           and therefore the dose to surrounding organs,&#xD;
&#xD;
        -  by using over one-hundred non-conplanar beams, the dose gradient between the prostate&#xD;
           and surrounding tissues may be superior to that achieved with conventional linear&#xD;
           accelerators,&#xD;
&#xD;
        -  the radiobiology of prostate cancer may favor large dose per fractions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher GI and GU toxicity observed during a 24 month follow up</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the rate of biochemical Disease-Free Survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of local failure, the rate of distant failure, the overall survival, the quality of life in generic and organ-specific domains</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period</description>
    <arm_group_label>SBRT</arm_group_label>
    <other_name>CyberKnife</other_name>
    <other_name>Trilogy</other_name>
    <other_name>True Beam</other_name>
    <other_name>Radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Gleason score 2-7&#xD;
&#xD;
          -  Biopsy within one year of date of registration&#xD;
&#xD;
          -  Clinical stage T1b-T2b, N0-Nx, M0-Mx (AJCC 6th Edition)&#xD;
&#xD;
          -  T-stage and N-stage determined by physical exam and available imaging studies&#xD;
             (ultrasound, CT, and/or MRI)&#xD;
&#xD;
          -  M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical&#xD;
             findings suggest possible osseous metastases.&#xD;
&#xD;
          -  PSA ≤ 20 ng/dL&#xD;
&#xD;
          -  Patients belonging in one of the following risk groups:&#xD;
&#xD;
          -  Low: CS T1b-T2a and Gleason 2-6 and PSA ≤ 10, or&#xD;
&#xD;
          -  Intermediate: CS T2b and Gleason 2-6 and PSA ≤ 10, or CS T1b-T2b, and Gleason 2-6 and&#xD;
             PSA ≤ 20 ng/dL, or Gleason 7 and PSA ≤ 10 ng/dL&#xD;
&#xD;
          -  Prostate volume: ≤ 100 cc&#xD;
&#xD;
          -  Determined using: volume = π/6 x length x height x width&#xD;
&#xD;
          -  Measurement from CT or ultrasound ≤90 days prior to registration.&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Completion of patient questionnaires:FACT-G questionnaire, AUA questionnaire, EPIC-26&#xD;
             questionnaire, SHIM questionnaire, Utilization of Sexual Medications/Devices&#xD;
             questionnaire&#xD;
&#xD;
          -  Consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior prostatectomy or cryotherapy of the prostate&#xD;
&#xD;
          -  Prior radiotherapy to the prostate or lower pelvis&#xD;
&#xD;
          -  Implanted hardware or other material that would prohibit appropriate treatment&#xD;
             planning or treatment delivery, in the investigator's opinion.&#xD;
&#xD;
          -  Chemotherapy for a malignancy in the last 5 years.&#xD;
&#xD;
          -  History of an invasive malignancy (other than this prostate cancer, or basal or&#xD;
             squamous skin cancers) in the last 5 years.&#xD;
&#xD;
          -  Hormone ablation for two months prior to enrollment, or during treat&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight E Heron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodney E Wegner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Adam Olson</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Stereotactic</keyword>
  <keyword>Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

